CoChat
Sign Up
Cited by 140Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events

Open access
Armitage, Jane, Holmes, Michael V., Preiss, David·2019·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2018.10.072PMC PMC6354546
Open this paper in CoChat — free accountOpen PDF

Abstract

Cholesteryl ester transfer protein (CETP) facilitates exchange of triglycerides and cholesteryl ester between high-density lipoprotein (HDL) and apolipoprotein B100-containing lipoproteins. Evidence from genetic studies that variants in the CETP gene were associated with higher blood HDL cholesterol, lower low-density lipoprotein cholesterol, and lower risk of coronary heart disease suggested that pharmacological inhibition of CETP may be beneficial. To date, 4 CETP inhibitors have entered phase 3 cardiovascular outcome trials. Torcetrapib was withdrawn due to unanticipated off-target effects that increased risk of death, and major trials of dalcetrapib and evacetrapib were terminated early for futility. In the 30,000-patient REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification) trial, anacetrapib doubled HDL cholesterol, reduced non-HDL cholesterol by 17 mg/dl (0.44 mmol/l), and reduced major vascular events by 9% over 4 years, but anaceptrapib was found to accumulate in adipose tissue, and regulatory approval is not being sought. Therefore, despite considerable initial promise, CETP inhibition provides insufficient cardiovascular benefit for routine use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2018.10.072

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Central Illustration
Graphical abstract Central IllustrationCC BY · PubMed Central
Central Illustration Effects of Cholesteryl Ester Transfer Protein Inhibitors and Genetic Variants on Major Cardiovascular Outcomes in the Context of Relevant Observational Epidemiology and Statin Therapy ↑ = increase; ↓ = decrease; ↔ = unchanged; BP = blood pressure; CETP = cholesteryl ester transfer protein; HDL-C = high-density lipoprotein cholesterol; HMG CoA = 3-hydroxy-3-methyl-glutaryl-coenzyme A; HMGCR = HMG CoA reductase; LDL-C = low-density lipoprotein cholesterol; MVE = major vascular events; N/A = not available; OR = odds ratio.
Central Illustration Effects of Cholesteryl Ester Transfer Protein Inhibitors and Genetic Variants on Major Cardiovascular Outcomes in the Context of Relevant Observational Epidemiology and Statin Therapy ↑ = increase; ↓ = decrease; ↔ = unchanged; BP = blood pressure; CETP = cholesteryl ester transfer protein; HDL-C = high-density lipoprotein cholesterol; HMG CoA = 3-hydroxy-3-methyl-glutaryl-coenzyme A; HMGCR = HMG CoA reductase; LDL-C = low-density lipoprotein cholesterol; MVE = major vascular events; N/A = not available; OR = odds ratio.CC BY · PubMed Central
Figure 1 The role of CETP in Lipid Metabolism and the Effect of CETP Inhibition on Circulating Lipoproteins (A) CETP in lipid metabolism and (B) the effect of CETP inhibition on circulating lipoprotein. CE = cholesteryl ester; CETP = cholesteryl ester transfer protein, HDL = high-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; trig = triglycerides; VLDL = very low-density lipoprotein.
Figure 1 The role of CETP in Lipid Metabolism and the Effect of CETP Inhibition on Circulating Lipoproteins (A) CETP in lipid metabolism and (B) the effect of CETP inhibition on circulating lipoprotein. CE = cholesteryl ester; CETP = cholesteryl ester transfer protein, HDL = high-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; trig = triglycerides; VLDL = very low-density lipoprotein.CC BY · PubMed Central
Figure 2 Associations of Clinical Trials of Lipid-Modifying Therapies, the Corresponding Genetic Proxies, and Risk of Coronary Heart Disease Clinical trials results are scaled to a 40-mg/dl lower non–HDL cholesterol and genetic associations are scaled to a 40-mg/dl lower apolipoprotein B100. Clinical trial data are taken from the original trials, with the exception of the CTT estimate, which is derived from Supplementary Figure 5 of the REVEAL trial. Genetic data are obtained from Ference et al. (13). Endpoints for the clinical trials are: 1) REVEAL: myocardial infarction or coronary death; 2) FOURIER: myocardial infarction; 3) CTT: myocardial infarction or coronary death; and 4) IMPROVE-IT: myocardial infarction. Endpoints for the genetic estimates are myocardial infarction, coronary death, coronary revascularization, or stroke. apo B = apolipoprotein B100; CTT = Cholesterol Treatment Trialists Collaboration; HMGCR = HMG CoA reductase; NPC1L1 = Niemann-Pick C1-Like 1; OR = odds ratio; PCSK9 = Proprotein Convertase Subtilisin/Kexin type 9; other abbreviations as in Figure 1.
Figure 2 Associations of Clinical Trials of Lipid-Modifying Therapies, the Corresponding Genetic Proxies, and Risk of Coronary Heart Disease Clinical trials results are scaled to a 40-mg/dl lower non–HDL cholesterol and genetic associations are scaled to a 40-mg/dl lower apolipoprotein B100. Clinical trial data are taken from the original trials, with the exception of the CTT estimate, which is derived from Supplementary Figure 5 of the REVEAL trial. Genetic data are obtained from Ference et al. (13). Endpoints for the clinical trials are: 1) REVEAL: myocardial infarction or coronary death; 2) FOURIER: myocardial infarction; 3) CTT: myocardial infarction or coronary death; and 4) IMPROVE-IT: myocardial infarction. Endpoints for the genetic estimates are myocardial infarction, coronary death, coronary revascularization, or stroke. apo B = apolipoprotein B100; CTT = Cholesterol Treatment Trialists Collaboration; HMGCR = HMG CoA reductase; NPC1L1 = Niemann-Pick C1-Like 1; OR = odds ratio; PCSK9 = Proprotein Convertase Subtilisin/Kexin type 9; other abbreviations as in Figure 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

Sorted by citations

See all 140

Related

Metadata

Authors
Armitage, J., Holmes, M. V., & Preiss, D.
Affiliations
University of Oxford (GB)
Corresponding author
Armitage, Jane
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2019-02
Volume
73
Issue
4
Pages
477-487
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2018.10.072
PMC
PMC6354546
OpenAlex
W2911625798
Cited by
140
References
46
Citations by year
2026: 9 · 2025: 10 · 2024: 19 · 2023: 11 · 2022: 15 · 2021: 30 · 2020: 28 · 2019: 17
FWCI
4.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute for Health and Care Research
  • British Heart Foundation (18/23/33512, RE/13/1/30181, FS/18/23/33512)
  • University of Oxford (RE/13/1/30181)
  • Merck Sharp and Dohme
  • Medical Research Council (13/1/30181, RE/13/1/30181)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
cholesteryl ester transfer protein, CETP inhibitors, cardiovascular events, HDL cholesterol, anacetrapib, torcetrapib, dalcetrapib, evacetrapib, coronary artery disease, non-HDL cholesterol, cardiovascular outcome trials, drug safety, adipose tissue accumulation
MeSH terms
Animals, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Clinical Trials, Phase III as Topic, Cholesterol Ester Transfer Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review